Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867009841604591616 |
|---|---|
| author | D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic |
| author_facet | D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic |
| collection | Wiley Open Access |
| contents | Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic Laryngoscope Investigative Otolaryngology ABSTRACTObjectiveThe primary objective of this study is to review the evidence for aspirin use to prevent the growth of vestibular schwannomas (VS) and to propose a prospective trial to determine the progression‐free survival of VS patients after up to 42 months of treatment with aspirin. Secondary study objectives are to determine the effect of aspirin on VS growth, hearing function, serum biomarker levels, and the quality of life, as well as to determine the tolerability of aspirin treatment and whether serum biomarker and salicylate levels predict the response to aspirin.Study DesignLiterature review.SettingSix academic and private medical centers.MethodsReview of recent English literature regarding prophylactic aspirin use for VS.ResultsThe retrospective reviews on the utility of aspirin to prevent VS growth are inconclusive. Eighty‐four patients have been enrolled in a prospective double‐blinded, placebo‐controlled trial thus far to determine the effect of aspirin on VS.ConclusionsCompletion of a robust study design is necessary. The current aspirin dose has been well tolerated, with minimal adverse events to date.Level of EvidenceReview of retrospective studies: Level 4; Proposed randomized, placebo‐controlled, double‐blinded clinical trial: Level 2. 10.1002/lio2.70121 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| doi_str_mv | 10.1002/lio2.70121 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_lio2_70121 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic Laryngoscope Investigative Otolaryngology Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal D. Bradley Welling Brian A. Neff Fred F. Telischi Neil Patel Konstantina M. Stankovic Laryngoscope Investigative Otolaryngology ABSTRACTObjectiveThe primary objective of this study is to review the evidence for aspirin use to prevent the growth of vestibular schwannomas (VS) and to propose a prospective trial to determine the progression‐free survival of VS patients after up to 42 months of treatment with aspirin. Secondary study objectives are to determine the effect of aspirin on VS growth, hearing function, serum biomarker levels, and the quality of life, as well as to determine the tolerability of aspirin treatment and whether serum biomarker and salicylate levels predict the response to aspirin.Study DesignLiterature review.SettingSix academic and private medical centers.MethodsReview of recent English literature regarding prophylactic aspirin use for VS.ResultsThe retrospective reviews on the utility of aspirin to prevent VS growth are inconclusive. Eighty‐four patients have been enrolled in a prospective double‐blinded, placebo‐controlled trial thus far to determine the effect of aspirin on VS.ConclusionsCompletion of a robust study design is necessary. The current aspirin dose has been well tolerated, with minimal adverse events to date.Level of EvidenceReview of retrospective studies: Level 4; Proposed randomized, placebo‐controlled, double‐blinded clinical trial: Level 2. 10.1002/lio2.70121 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title | Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal |
| topic | Laryngoscope Investigative Otolaryngology |
| url | https://onlinelibrary.wiley.com/doi/10.1002/lio2.70121 |